Brief: MHRA Agrees With Galmed's Plan To Use Aramchol Meglumine In Part Of Phase 3 Study

Eocene

16/08/2021 13:07

Aug 16 (Reuters) - Galmed Pharmaceuticals Ltd  GLMD.O :
    * MHRA AGREES WITH GALMED'S PLAN TO USE ARAMCHOL MEGLUMINE
IN
RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PART OF PHASE 3 ARMOR
STUDY
    * GALMED PHARMACEUTICALS LTD - MHRA AGREEMENT FOLLOWS
SIMILAR
AGREEMENT FROM FDA

Source text for Eikon:  ID:nPnkJF4ka 
Further company coverage:  GLMD.O 

 ((Reuters.Briefs@thomsonreuters.com;))